Research ArticleArticle
Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
Christoph Tappeiner, Elisabetta Miserocchi, Bahram Bodaghi, Kaisu Kotaniemi, Friederike Mackensen, Valeria Gerloni, Pierre Quartier, Thomas Lutz and Arnd Heiligenhaus
The Journal of Rheumatology February 2015, jrheum.140410; DOI: https://doi.org/10.3899/jrheum.140410
Christoph Tappeiner
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Elisabetta Miserocchi
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Bahram Bodaghi
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Kaisu Kotaniemi
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Friederike Mackensen
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Valeria Gerloni
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Pierre Quartier
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Thomas Lutz
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
Arnd Heiligenhaus
From the Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland; Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen, and Department of Ophthalmology, and Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine, Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, and Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University, Milan, Italy; Department of Ophthalmology, Hôpital Pitié-Salpêtrière, and Paris-Descartes University, IMAGINE and Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Paris, France; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.C. Tappeiner was supported by an unrestricted grant from the Swiss Foundation for Grants in Biology and Medicine/Swiss National Science Foundation and Novartis. P. Quartier is involved in clinical trials with abatacept.C. Tappeiner, MD, Department of Ophthalmology, Inselspital, University of Bern, and Department of Ophthalmology, St. Franziskus Hospital, Münster; E. Miserocchi, MD, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele; B. Bodaghi, MD, PhD, Department of Ophthalmology, Hôpital Pitié-Salpêtrière; K. Kotaniemi, MD, PhD, Department of Ophthalmology, Helsinki University Hospital; F. Mackensen, MD, Department of Ophthalmology and Interdisciplinary Uveitis Center, University of Heidelberg; V. Gerloni, MD, Department of Rheumatology, Pediatric Rheumatology Unit, Istituto Ortopedico G. Pini University;P. Quartier, MD, Paris-Descartes University, IMAGINE and Pediatric Immunology- Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital; T. Lutz, MD, Department of General Pediatrics, Centre for Pediatric and Adolescent Medicine and Interdisciplinary Uveitis Center, University of Heidelberg; A. Heiligenhaus, MD, Department of Ophthalmology, St. Franziskus Hospital, Münster, and University Duisburg-Essen. Address correspondence to Dr. A. Heiligenhaus, Department of Ophthalmology and Ophtha Lab, St. Franziskus Hospital, Hohenzollernring 74, 48145 Münster, Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de Accepted for publication December 19, 2014.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
Christoph Tappeiner, Elisabetta Miserocchi, Bahram Bodaghi, Kaisu Kotaniemi, Friederike Mackensen, Valeria Gerloni, Pierre Quartier, Thomas Lutz, Arnd Heiligenhaus
The Journal of Rheumatology Feb 2015, jrheum.140410; DOI: 10.3899/jrheum.140410
Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
Christoph Tappeiner, Elisabetta Miserocchi, Bahram Bodaghi, Kaisu Kotaniemi, Friederike Mackensen, Valeria Gerloni, Pierre Quartier, Thomas Lutz, Arnd Heiligenhaus
The Journal of Rheumatology Feb 2015, jrheum.140410; DOI: 10.3899/jrheum.140410